PRINCIPAL FINANCIAL GROUP INC - INTERCEPT PHARMACEUTICALS IN ownership

INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 157 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q3 2023. The put-call ratio across all filers is 2.78 and the average weighting 0.2%.

Quarter-by-quarter ownership
PRINCIPAL FINANCIAL GROUP INC ownership history of INTERCEPT PHARMACEUTICALS IN
ValueSharesWeighting
Q3 2023$738,485
+141.5%
39,832
+44.1%
0.00%
Q2 2023$305,765
+15.3%
27,646
+40.0%
0.00%
Q1 2023$265,283
-6.5%
19,753
-13.9%
0.00%
Q4 2022$283,867
+2.9%
22,948
+16.0%
0.00%
Q3 2022$276,000
-52.7%
19,791
-53.2%
0.00%
Q2 2022$584,000
-43.9%
42,322
-33.9%
0.00%
-100.0%
Q1 2022$1,041,000
-32.6%
63,994
-32.5%
0.00%0.0%
Q4 2021$1,544,000
+12.9%
94,811
+3.0%
0.00%0.0%
Q3 2021$1,368,000
-27.0%
92,092
-1.8%
0.00%0.0%
Q2 2021$1,873,000
-15.9%
93,796
-2.7%
0.00%
-50.0%
Q1 2021$2,226,000
+1.1%
96,431
+8.2%
0.00%0.0%
Q4 2020$2,201,000
-12.6%
89,115
+46.7%
0.00%0.0%
Q3 2020$2,518,000
+31.4%
60,736
+51.8%
0.00%0.0%
Q2 2020$1,916,000
+267.8%
40,000
+383.4%
0.00%
+100.0%
Q1 2020$521,000
-47.6%
8,275
+3.0%
0.00%0.0%
Q4 2019$995,000
+79.3%
8,032
-3.9%
0.00%
Q3 2019$555,000
-8.9%
8,361
+9.3%
0.00%
-100.0%
Q2 2019$609,000
-73.5%
7,653
-62.7%
0.00%
-50.0%
Q1 2019$2,297,000
+14.4%
20,533
+3.1%
0.00%0.0%
Q4 2018$2,007,000
+97.2%
19,914
+147.2%
0.00%
+100.0%
Q3 2018$1,018,000
+74.3%
8,056
+15.7%
0.00%0.0%
Q2 2018$584,000
+110.1%
6,962
+54.3%
0.00%
Q1 2018$278,000
+16.8%
4,511
+10.7%
0.00%
Q4 2017$238,000
-87.5%
4,074
-74.0%
0.00%
-100.0%
Q2 2017$1,901,000
+10.5%
15,699
+3.1%
0.00%0.0%
Q1 2017$1,721,000
+2.1%
15,222
-1.9%
0.00%0.0%
Q4 2016$1,686,000
-33.9%
15,520
+0.2%
0.00%
-33.3%
Q3 2016$2,550,000
+27.4%
15,491
+10.4%
0.00%0.0%
Q2 2016$2,002,000
+13.8%
14,033
+2.4%
0.00%0.0%
Q1 2016$1,760,000
-14.2%
13,705
-0.2%
0.00%0.0%
Q4 2015$2,052,000
-9.9%
13,734
-0.0%
0.00%
-25.0%
Q3 2015$2,278,000
-12.8%
13,738
+27.0%
0.00%0.0%
Q2 2015$2,611,000
-11.8%
10,818
+3.0%
0.00%0.0%
Q1 2015$2,960,000
+80.7%
10,5000.0%0.00%
+33.3%
Q4 2014$1,638,000
-32.8%
10,500
+1.9%
0.00%
-25.0%
Q3 2014$2,438,000
+0.0%
10,3000.0%0.00%0.0%
Q2 2014$2,437,000
-45.2%
10,300
-23.6%
0.00%
-50.0%
Q1 2014$4,445,00013,4780.01%
Other shareholders
INTERCEPT PHARMACEUTICALS IN shareholders Q3 2023
NameSharesValueWeighting ↓
Samsara BioCapital, LLC 640,688$14,787,0002.73%
DeepCurrents Investment Group LLC 416,800$9,620,0000.33%
DUALITY ADVISERS, LP 105,668$2,439,0000.21%
EULAV Asset Management 335,000$7,732,0000.21%
Virtus ETF Advisers LLC 19,375$447,0000.19%
Hennion & Walsh Asset Management, Inc. 135,214$3,121,0000.19%
PDT Partners, LLC 110,592$2,552,0000.18%
KETTLE HILL CAPITAL MANAGEMENT, LLC 70,256$1,622,0000.16%
ALTRINSIC GLOBAL ADVISORS LLC 168,800$3,896,0000.12%
WOODWARD DIVERSIFIED CAPITAL, LLC 8,939$206,0000.12%
View complete list of INTERCEPT PHARMACEUTICALS IN shareholders